Scancell Lines Up Nasdaq Funding as Melanoma Vaccine Heads to Phase 3
Scancell has secured funding for a proposed Nasdaq listing as the UK-based biotech pushes its lead cutaneous melanoma programme into Phase 3 development, according to Yahoo Finance UK.